Discontinuation of GLP-1 therapy in diabetes linked to twofold increase in risk of heart attack, stroke, and death
An observational study linked the discontinuation of GLP-1 therapy in people with type 2 diabetes to a twofold higher risk of heart attack, stroke, or death.

Researchers identified an association between treatment discontinuation and the cumulative risk of non-fatal heart attack, non-fatal stroke, or death from any cause. The study was published in *The Lancet Regional Health Europe*.
The analysis included electronic medical records of over 80,000 people with type 2 diabetes without established cardiovascular disease. All had started taking GLP-1 medications, after which some participants discontinued therapy. Those who stopped treatment had a higher risk than those who continued it.
The difference was particularly notable among patients with obesity: after discontinuing the medications, their cardiovascular risk increased by 127%, whereas in people without obesity, the increase was 61%.
The authors emphasize that the study was observational and does not prove a direct causal relationship. Individuals who discontinued treatment may have initially had a more severe condition or other risk factors. After stopping the medications, changes in weight, blood sugar levels, and blood pressure were minor and did not fully explain the differences between the groups.
Most participants received previous-generation GLP-1 medications. Only a small proportion took semaglutide, and tirzepatide was not included in the analysis, as it had not yet entered the Italian market at the time of the study.





